ABVXCongressional Stock Trades
ABIVAX Société Anonyme
Biotechnology
Congressional stock trades in ABIVAX Société Anonyme (ABVX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
1
Politicians Trading
1
Last Traded
Jul 10, 2026
Price History
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
1 members of Congress have disclosed 1 trades in ABIVAX Société Anonyme (ABVX). Most active: Ro Khanna (1).
Across all disclosures, members of Congress reported 1 purchases and 0 sales of ABIVAX Société Anonyme (ABVX). The most recent trade was on Jul 10, 2026.
Ro Khanna disclosed buying ABIVAX Société Anonyme (ABVX) on Jul 10, 2026, valued at $15,001 - $50,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.